ArticleHepatology international2025

HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.

Shuangyan Tang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.